^
Association details:
| Biomarker: | miR-200-b overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Tissue MicroRNA Expression as a Predictor of Response to Immunotherapy in NSCLC Patients
Published date:
02/08/2021
Excerpt:
The study included 60 patients with NSCLC who underwent first or second line immunotherapy with pembrolizumab or nivolumab....In univariate analysis, the median PFS was significantly higher in patients with high miR-200b expression (HR=0.4253, 95%CI: 0.1737-1.0417, p=0.05) and high miR-508 expression (HR=0.4401, 95%CI: 0.1903-1.0178, p=0.05) and with low expression of miR-429 (HR=0.1288, 95%CI: 0.01727-0.9606, p=0.0456) compared to patients with low and high expression of these molecules, respectively.
DOI:
10.3389/fonc.2020.563613
